ArticleFrontiers in immunology2025
Evaluating the triglyceride-glucose index as a biomarker for inflammatory bowel disease risk: insights from a UK Biobank prospective study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn's disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory condition with rising global incidence. This study examines the association between the triglyceride-glucose (TyG) index, a marker of insulin resistance, and both the risk and prognosis of IBD. Methods: This study analyzed data from 327,089 participants in the UK Biobank. The TyG index was calculated based on fasting triglyceride and glucose levels, and participants were categorized into quartiles. Cox proportional hazards models, restricted cubic splines (RCS), subgroup analyses, and mediation analyses were employed to explore the association between TyG and the risk of UC and CD. Covariates were adjusted for age, sex, race, socioeconomic and lifestyle factors, physical activity, common chronic diseases, and polygenic risk scores. Multiple sensitivity analyses were conducted to ensure the robustness of the results. Results: An elevated TyG index was significantly associated with an increased risk of IBD. For each unit increase in TyG, the risk of UC increased by 14.3% (HR: 1.143, 95% CI: 1.053-1.241), while the risk of CD increased by 13.8% (HR: 1.138, 95% CI: 1.006-1.286). Participants in the highest TyG quartile had a 28.0% higher risk of CD (HR: 1.280, 95% CI: 1.050-1.560) and a 17.8% higher risk of UC (HR: 1.178, 95% CI: 1.028-1.351) compared to those in the lowest quartile. Mediation analysis revealed that the association between TyG and the incidence of CD and UC was mediated by multiple factors, including white blood cell count, mean corpuscular hemoglobin, C-reactive protein, total bilirubin, neutrophil count, reticulocyte percentage, and high-light scatter reticulocyte percentage. The proportion of mediation effects ranged from 1.44% to 30.97%. Conclusion: This study is the first to systematically investigate the relationship between the TyG index and both the risk and prognosis of IBD, using a large cohort from the UK Biobank. The findings reveal a significant positive association between the TyG index and the risk of developing UC and CD, suggesting that a higher TyG index may serve as an independent predictor of IBD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.